文献速递心力衰竭与心肌病

恩格列净在心力衰竭中的利尿与心肾效应

Empagliflozin in Heart Failure: Diuretic and Cardiorenal Effects.
PubMed 文献 · Circulation · 2020-05-15

该随机、安慰剂对照交叉研究纳入20例2型糖尿病合并慢性稳定性心力衰竭患者,比较恩格列净10mg每日一次与安慰剂的利尿及心肾效应。结果显示恩格列净显著增加尿钠排泄,尤其与袢利尿剂联用时,并降低血容量和血浆容量,且不引起神经激素激活、电解质丢失或肾功能恶化。

要点

  • 恩格列净单药及与布美他尼联用均显著增加尿钠排泄。
  • 恩格列净治疗14天降低血容量和血浆容量,不激活神经激素。
  • 未观察到钾丢失或肾功能损害,血镁和尿酸水平改善。

核心结论

  • 恩格列净产生显著尿钠排泄,尤其与袢利尿剂联用时,改善血容量,且不引起电解质丢失、肾功能不全或神经激素激活。

研究设计与样本

  • 随机、安慰剂对照交叉研究,纳入20例2型糖尿病合并慢性稳定性心力衰竭患者,恩格列净10mg每日一次与安慰剂对比,各治疗14天,洗脱期2周。

主要发现

  • 口服恩格列净3小时尿糖排泄增加27倍(P<0.0001)。
  • 恩格列净单药较安慰剂显著增加钠分数排泄(1.2±0.7% vs 0.7±0.4%,P=0.001)。
  • 与布美他尼联用时间协同增加钠分数排泄(5.8±2.5% vs 3.9±1.9%,P=0.001)。
  • 治疗14天,恩格列净组血容量减少-208 mL(IQR -536至153 mL) vs 安慰剂组-14 mL(IQR -282至335 mL),P=0.035。
  • 血浆容量减少-138 mL(IQR -379至154±453 mL),P=0.04。

关键数值与推荐

  • 钠分数排泄:恩格列净单药1.2±0.7% vs 安慰剂0.7±0.4%,P=0.001。
  • 与布美他尼联用钠分数排泄:5.8±2.5% vs 3.9±1.9%,P=0.001。
  • 血容量变化:-208 mL(IQR -536至153 mL) vs -14 mL(IQR -282至335 mL),P=0.035。
  • 血浆容量变化:-138 mL(IQR -379至154±453 mL),P=0.04。
  • 去甲肾上腺素变化组间比较P=0.02,其他神经激素相似(P<0.34);无钾丢失证据(P=0.20),肾功能生物标志物无差异(P>0.11);血镁(P<0.001)和尿酸(P=0.008)改善。

临床怎么用

  • 恩格列净可用于心力衰竭患者容量管理,尤其与袢利尿剂联用增强利尿效果。
  • 使用恩格列净时无需担心神经激素激活、钾丢失或肾功能恶化。

局限性

  • 样本量小(20例),仅为2型糖尿病合并慢性稳定性心力衰竭患者。
  • 研究周期短(14天),长期效应未评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Sodium-glucose cotransporter-2 inhibitors improve heart failure-related outcomes. The mechanisms underlying these benefits are not well understood, but diuretic properties may contribute. Traditional diuretics such as furosemide induce substantial neurohormonal activation, contributing to the limited improvement in intravascular volume often seen with these agents. However, the proximal tubular site of action of the sodium-glucose cotransporter-2 inhibitors may help circumvent these limitations. METHODS: Twenty patients with type 2 diabetes mellitus and chronic, stable heart failure completed a randomized, placebo-controlled crossover study of empagliflozin 10 mg daily versus placebo. Patients underwent an intensive 6-hour biospecimen collection and cardiorenal phenotyping at baseline and again after 14 days of study drug. After a 2-week washout, patients crossed over to the alternate therapy with the above protocol repeated. RESULTS: Oral empagliflozin was rapidly absorbed as evidenced by a 27-fold increase in urinary glucose excretion by 3 hours (P<0.0001). Fractional excretion of sodium increased significantly with empagliflozin monotherapy versus placebo (fractional excretion of sodium, 1.2±0.7% versus 0.7±0.4%; P=0.001), and there was a synergistic effect in combination with bumetanide (fractional excretion of sodium, 5.8±2.5% versus 3.9±1.9%; P=0.001). At 14 days, the natriuretic effect of empagliflozin persisted, resulting in a reduction in blood volume (-208 mL [interquartile range, -536 to 153 mL] versus -14 mL [interquartile range, -282 to 335 mL]; P=0.035) and plasma volume (-138 mL, interquartile range, -379 to 154±453 mL; P=0.04). This natriuresis was not, however, associated with evidence of neurohormonal activation because the change in norepinephrine was superior (P=0.02) and all other neurohormones were similar (P<0.34) during the empagliflozin versus placebo period. Furthermore, there was no evidence of potassium wasting (P=0.20) or renal dysfunction (P>0.11 for all biomarkers), whereas both serum magnesium (P<0.001) and uric acid levels (P=0.008) improved. CONCLUSIONS: Empagliflozin causes significant natriuresis, particularly when combined with loop diuretics, resulting in an improvement in blood volume. However, off-target electrolyte wasting, renal dysfunction, and neurohormonal activation were not observed. This favorable diuretic profile may offer significant advantage in the management of volume status in patients with heart failure and may represent a mechanism contributing to the superior long-term heart failure outcomes observed with these agents. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03027960.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Griffin M, Rao VS, Ivey-Miranda J, et al. Empagliflozin in Heart Failure: Diuretic and Cardiorenal Effects. Circulation. 2020. PMID: 32410463. doi:10.1161/CIRCULATIONAHA.120.045691

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。